NNC0385-0434 A 100 mg

DRUG2 trials

Sponsors

Novo Nordisk A/S

Conditions

Atherosclerotic Cardiovascular DiseaseChronic Kidney Disease

Phase 1

A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney Function

TerminatedNCT05094934

Novo Nordisk A/SChronic Kidney Disease

Start: 2021-11-09End: 2022-08-24Updated: 2023-12-26

Phase 2

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

CompletedNCT04992065

Novo Nordisk A/SAtherosclerotic Cardiovascular Disease

Start: 2021-08-03End: 2022-06-20Updated: 2025-06-08

Related Papers

PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial.

2024-02-0118 citations